UBS O’Connor expands with healthcare-focused investment team

New York, February 22, 2022 – UBS O’Connor, the multi-strategy hedge fund manager within UBS Asset Management, announced today that it has hired Jason Bonadio MD, Robert Sweeney MD, and Adam Sandler MD to manage a relative value equity strategy focusing on the healthcare therapeutics industry.

Our new investment team at O’Connor brings a combination of biomedical expertise and investment experience that enables us to identify healthcare companies trading well below their intrinsic value. This segment of the market, which has always been prone to high dispersion of returns and high barriers to investment participation, due to the scientific and data complexity of the industry, creates an investment opportunity set ideal for alpha generation and uncorrelated returns.

Kevin Russell, Chief Investment Officer of O’Connor.

Dr. Jason Bonadio joins as a Healthcare Portfolio Manager. Prior to this role, he co-founded Alera Partners, a long/short equity healthcare fund investing in the biotechnology, medical technology, pharmaceutical and life science tools sectors. Dr. Bonadio was also a founding partner and a co-portfolio manager of the FrontPoint Healthcare Funds.

Dr. Robert Sweeney joins as a Healthcare Research Analyst. Dr. Sweeney is a board-eligible surgeon that joined Alera Partners in 2021. Previously, he worked as a sell-side equity research analyst at H.C. Wainwright, with coverage across therapeutic areas and medical devices. He is currently a Ph.D. candidate in Immunology at the Icahn School of Medicine at Mount Sinai in NYC.

Dr. Adam Sandler joins as a Healthcare Research Analyst. Dr. Sandler is currently the chief resident in the Department of Occupational Medicine at Mount Sinai. He joined Alera Partners in 2021 and was previously a healthcare analyst at Guidepoint Global. After graduating, cum laude from Harvard University in 2004, he received awards for his work from the New York Academy of Medicine, Crohn’s and Colitis Foundation of America, and Adenosine Therapeutics at Mount Sinai School of Medicine.

O’Connor has USD 11.2 billion in assets under management as of February 1, 2022. UBS Asset Management is a large scale asset manager with over USD 1.2 trillion in invested assets across its traditional asset management, hedge fund, real estate, infrastructure and private equity businesses.

Asset Management is a large-scale asset manager with a presence in 23 markets. It offers investment capabilities and investment styles across all major traditional and alternative asset classes to institutions, wholesale intermediaries and wealth management clients around the world. It is a leading fund house in Europe, the largest mutual fund manager in Switzerland, the second largest fund of hedge funds manager and one of the largest real assets investment managers in the world.

O'Connor is a multi-strategy hedge fund manager within UBS Asset Management, with complete independence in regard to investment decision-making. O’Connor has over 40 years of institutional experience in trading and market making and 20 years’ experience as a hedge fund manager with a strong focus on relative value investing and risk management. O'Connor's capabilities cover a wide range of investment programs and manage over USD 11.2 billion in assets (as of February 1, 2022) on behalf of institutional and high net worth clients. The firm has a global operating platform with offices located in New York, Chicago, Stamford, London, Hong Kong, Shanghai and Singapore.

This publication is not to be construed as a solicitation of an offer to buy or sell any securities or other financial instruments relating to UBS AG or its affiliates in Switzerland, the United States or any other jurisdiction. UBS specifically prohibits the redistribution or reproduction of this material in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any errors or omissions. All such information and opinions are subject to change without notice. Please note that past performance is not a guide to the future. With investment in real estate/infrastructure/private equity (via direct investment, closed- or open-end funds) the underlying assets are illiquid, and valuation is a matter of judgment by a valuer. The value of investments and the income from them may go down as well as up and investors may not get back the original amount invested. Any market or investment views expressed are not intended to be investment research. The document has not been prepared in line with the requirements of any jurisdiction designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The information contained in this document does not constitute a distribution, nor should it be considered a recommendation to purchase or sell any particular security or fund. A number of the comments in this document are considered forward-looking statements. Actual future results, however, may vary materially. The opinions expressed are a reflection of UBS Asset Management’s best judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed. Furthermore, these views are not intended to predict or guarantee the future performance of any individual security, asset class, markets generally, nor are they intended to predict the future performance of any UBS Asset Management account, portfolio or fund. Source for all data/charts, if not stated otherwise: UBS Asset Management, UBS O’Connor. The views expressed are as of December 2021 and are a general guide to the views of UBS Asset Management, UBS O’Connor. All information as at December 2021 unless stated otherwise. Published December 2021.
Approved for global use.

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. Other marks may be trademarks of their respective owners. All rights reserved.